TDC
NBRV

Thompson Davis & Co’s Nabriva Therapeutics plc Ordinary Shares Ireland NBRV Stock Holding History

Thompson Davis & Co’s Portfolio NBRV Stock Details NBRV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-1
Closed -$2K – 1171
2017
Q3 		$2K Buy
+1
New +$2.35K ﹤0.01% 1030

Other funds holding NBRV

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
HIM
Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Thompson Davis & Co's NBRV Position: Q4 2017 in Review

Thompson Davis & Co sold out of Nabriva Therapeutics plc Ordinary Shares Ireland (NBRV) in Q4 2017, closing a stake of 1 share — an estimated $2K sold.

Thompson Davis & Co first reported a position in NBRV in Q3 2017 and held it in 1 quarter. The position peaked at $2K in Q3 2017. 45 funds tracked by Wall St. Rank hold NBRV as of Q4 2017.

  • Thompson Davis & Co reported no remaining Nabriva Therapeutics plc Ordinary Shares Ireland position as of Q4 2017 after selling out during the quarter.
  • Thompson Davis & Co sold 1 Nabriva Therapeutics plc Ordinary Shares Ireland share in Q4 2017, an estimated $2K.
  • Thompson Davis & Co first reported a position in Nabriva Therapeutics plc Ordinary Shares Ireland in Q3 2017 and held it in 1 quarter.
  • Thompson Davis & Co's Nabriva Therapeutics plc Ordinary Shares Ireland position peaked at $2K in Q3 2017.
  • 45 funds tracked by Wall St. Rank held Nabriva Therapeutics plc Ordinary Shares Ireland as of Q4 2017.

Based on Thompson Davis & Co's 13F filing for Q4 2017, filed 5 Feb 2018.